Intellia Therapeutics to Present at October Healthcare Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. BILL
4. ADI
5. SPY

6. MRK
7. MRNA
8. TJX
9. DE
10. LOW

Get Alerts NTLA Hot Sheet

Price: $12.48 -6.02%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in October:

Monday, October 1, 2018Cantor Fitzgerald Healthcare ConferenceLocation: New York, NYTime: 4:40pm ET

Tuesday, October 2, 2018Leerink Partners Roundtable Series: Rare Disease & OncologyLocation: New York, NYTime: 10:30am ET

Tuesday, October 9, 2018Chardan Genetic Medicines ConferenceLocation: New York, NYTime: 1:30pm ET

A live webcast of Intellia’s presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases by replacing patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Investor Contact: Lindsey Trickett Vice President, Investor Relations +1 857-285-6211[email protected]

Media Contact:Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 857-706-1071 [email protected]